Financial Performance - Net profit attributable to shareholders rose by 30.39% to CNY 19,132,669.99 for Q1 2025, up from CNY 14,673,681.53 in the same period last year[10] - Operating revenue for Q1 2025 reached CNY 104,177,997.52, reflecting a growth of 13.04% compared to CNY 92,158,215.06 in Q1 2024[10] - The company reported a significant increase in investment income by 269.97% to CNY 1,403,223.67, due to higher returns from structured deposits and low-risk investments[13] - The total comprehensive income for Q1 2025 was ¥19,132,669.99, compared to ¥14,673,681.53 in Q1 2024, indicating a strong performance[38] - Operating profit for Q1 2025 was ¥22,329,633.86, an increase of 28.3% from ¥17,416,882.06 in Q1 2024[38] Cash Flow - The net cash flow from operating activities increased by 29.86% to CNY 19,967,691.32, compared to CNY 15,376,630.73 in the previous year[10] - Cash inflow from operating activities increased to CNY 109,889,613.19 in Q1 2025, up from CNY 91,034,853.10 in Q1 2024[43] - The company reported a net cash outflow from financing activities of CNY -26,347,107.13 in Q1 2025, contrasting with a net inflow of CNY 22,068,986.34 in Q1 2024[42] - Cash flow from investment activities increased by 118.53% to 38,617,287.68 RMB, driven by the redemption of structured deposits and the issuance of bank acceptance bills for fixed asset payments[14] - The company received CNY 20,679,280.00 in other operating cash in Q1 2025, a substantial increase from CNY 1,000,130.80 in Q1 2024[43] Assets and Liabilities - Total assets increased by 5.68% to CNY 849,583,307.77 as of March 31, 2025, compared to CNY 803,935,578.14 at the end of 2024[10] - The company's asset-liability ratio (consolidated) improved to 19.72% from 17.84% year-on-year[10] - Current liabilities rose to ¥161,800,354.49 from ¥137,598,061.35, reflecting an increase of approximately 17.6%[32] - Total liabilities increased to ¥167,570,141.98 from ¥143,457,042.34, marking a growth of around 16.8%[33] - Shareholders' equity rose to ¥682,013,165.79 from ¥660,478,535.80, showing an increase of about 3.3%[33] Shareholder Information - Major shareholder Li Songnian holds 59.87% of the total shares, amounting to 46,512,000 shares[20] - The total number of ordinary shares remained at 77,688,000, with 45.83% being unrestricted shares[19] - The total number of shares held by major shareholders is 57,642,490, representing 74.20% of the total shares[21] Operational Insights - The company plans to continue expanding its market presence, focusing on both domestic and international sales[13] - The company is in the process of merging its wholly-owned subsidiary Wuxi Jinghong Biotechnology Co., Ltd. into Wuxi Jinghai, with the merger expected to complete soon[25] - The company expects to sell goods worth 5,000,000 yuan to related party Wuxi Jingyang Biotechnology Co., Ltd. in 2025, with no sales recorded as of the reporting period[25] Other Financial Metrics - The gross profit margin showed slight improvement due to enhanced cost control measures[13] - Research and development expenses rose to ¥4,502,779.43 in Q1 2025, compared to ¥3,732,394.90 in Q1 2024, marking a 20.6% increase[37] - Tax expenses for Q1 2025 were ¥3,164,246.82, up from ¥2,673,200.53 in Q1 2024, reflecting a 18.3% increase[38] - The company reported a 71.39% decrease in tax payments to 783,501.04 RMB, attributed to reduced income tax liabilities from last year's profit decline[14]
无锡晶海(836547) - 2025 Q1 - 季度财报